SCHEMBL4920495

SCHEMBL4920495

CC(=O)c1ccc(NC(=O)Nc2cc3ccccc3s2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.59
RAB9A P51151 8/20 0.59
NPC1 O15118 8/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
TAAR1 Q96RJ0 1/20 0.59
KMT2A Q03164 8/20 0.54
ALDH1A1 P00352 3/20 0.52
TP53 P04637 2/20 0.52
MEN1 O00255 7/20 0.50
HTT P42858 2/20 0.50
NLRP1 Q9C000 1/20 0.50
POLB P06746 2/20 0.48
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
EGFR P00533 1/20 0.46
PIK3CA P42336 1/20 0.46
GAA P10253 3/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4919628 0.86 SMN1; SMN2 (0.55) MAPTRAB9ANPC1SMN1; SMN2TAAR1
SCHEMBL4921114 0.83 MAPT (0.52) MAPTRAB9ANPC1SMN1; SMN2TAAR1
SCHEMBL4918661 0.83 KDM4E (0.49) MAPTRAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL10816508 0.78 PKM (0.52) RAB9ANPC1SMN1; SMN2CA12CA1
SCHEMBL14470417 0.77 RAB9A (0.73) MAPTRAB9ANPC1SMN1; SMN2TAAR1
SCHEMBL1719786 0.76 RAB9A (1.00) MAPTRAB9ANPC1SMN1; SMN2TAAR1
SCHEMBL3633396 0.75 NPC1 (0.84) MAPTRAB9ANPC1SMN1; SMN2TAAR1
SCHEMBL4926273 0.75 MAPT (0.57) MAPTRAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL11993580 0.75 NPC1 (0.75) MAPTRAB9ANPC1SMN1; SMN2TAAR1
SCHEMBL31000016 0.73 MMP2 (0.67) MAPTRAB9ANPC1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885RAB9A 3359/4885NPC1 148/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885RAB9A 3359/4885NPC1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.